Clinical Trials Browser

Interventional × Neoplasms × Bendamustine Hydrochloride × Clear all

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT03755804 2026-02-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2 Active not recruiting

232 enrolled

Lymphoid

Hodgkin Disease, Neoplasms

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1 Active not recruiting

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04510636 2024-03-22

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

72 enrolled

Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 2 Completed

99 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

18 enrolled

Lymphoid

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01657955 2012-08-06

CLL

Phase 3 Unknown

96 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00863850 2012-04-23

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy

Phase 1 Completed

6 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

EPCORE™FL-2

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

CLL

Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy